License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness.
StemSight and ERS Genomics focus on collaboration
- Post author:
- Post published:
- Post category:uncategorized
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2026 Diabetes Prevention Awareness Center.